Venture Capital

Fractyl Raises $55M In Series E Financing To Advance Revita Dmr For Type 2 Diabetes

by vcaonline.com posted 12months ago 88 views
Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date. LEXINGTON, Mass., August 6, 2020-- Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced a first close of $55 million in a Series E financing.

In this article